|
|
List of sponsors 
If you are interested in sponsorship opportunities at this event then please contact:
Mike Wind, Sponsorship Manager
Email: michael.wind@terrapinn.com
Tel: +44 (0)207 827 5945
Fax: +44 (0)207 242 1508
|
Gold sponsors
|
Pall Corporation is the global leader in the rapidly growing field of filtration, separations and purification, especially in the biopharmaceutical industry for the production of biotech and biopharmaceutical products.
Pall's Life Sciences Group is fully integrated to offer product lines that start in the laboratory with drug discovery, gene manipulation and proteomics applications, and extend into drug development, process scale up, through to full drug manufacturing production and patient delivery. Pall's extensive expertise helps its customers throughout the drug approval regulatory process, and its filtration systems and validation services offer drug manufacturers the quickest and surest path through the regulatory process and onto the market. As Mr Jerold M. Martin, Senior Vice President and Global Technical Director for Pall Life Sciences' BioPharmaceuticals division said, "Pall Corporation is committed to developing the most advanced, cost-effective virus filtration products that maximize customers' opportunity for success."
|
Cardinal Health is a full-service contract manufacturer of biotech and sterile pharmaceutical products. Our multiple manufacturing facilities, combined with our experience with all types of sterile products, provide flexible capacity and efficiencies. From clinical quantities to full-scale production, we can develop and manufacture virtually any sterile product, including:
· Lyophilization
· Prefilled syringes
· Blow/Fill/Seal
· Vials and ampoules
Tel (toll-free): 1-866-720-3148
Email: bsls.sales@cardinal.com
www.cardinal.com/pts
|
Cobra Biomanufacturing is a company focused on the provision of innovative manufacturing solutions for the production of biopharmaceutical products and gene medicines. We provide world-class GMP contract manufacturing solutions for the development of biopharmaceutical products from discovery through clinical trial manufacture. At Cobra we can offer our customers the innovative production technologies, expert manufacturing skills and high level of analytical capabilities they demand.
|
Cocktail sponsors
|
With manufacturing facilities in USA, UK and Australia, SAFC Biosciences provides innovative cell culture reagents and services for companies developing and producing biopharmaceuticals using mammalian and insect cell culture methods. From upstream processing to downstream purification, formulation and drug delivery, SAFC Biosciences’ portfolio supports the drug pipeline from R&D through bulk manufacture.
|
Lyon BioAdvisor. For doing business in France, Lyon BioAdvisor offers you a business opportunity to develop your activity and helps you to invest in France.
Specific business opportunities in immuno-therapy / cancer
|
Supporting sponsor
|
BioSante is an emerging pharmaceutical company developing a robust product pipeline of hormone therapy products to treat both men and women.
BioSante also is developing its calcium phosphate nanoparticulate-based platform technology (CAP) for novel vaccines, vaccine adjuvants and drug delivery systems.
|
Associate sponsor
|
Immutep's lead product, ImmuFact® IMP321, is a highly potent T cell immunostimulatory factor enhancing dendritic cell maturation and cross-presentation of antigens to CD8+ T cells. As a result, strong and sustained anti-tumour or anti-viral cytotoxic T cell responses are obtained when IMP321 is coinjected with antigens.
Another technology, ImmuTune®, uses antibodies to control signalling into effector T cells or Tregs to modulate the T cell response.
Immutep is conducting Phase I/II studies with IMP321 alone and combined with two standard antigens. A Phase I trial in cancer patients will start shortly with IMP321 alone.
Immutep is setting up partnerships for ImmuFact with companies developing therapeutic vaccines, either cell-based, or using novel antigens, vectorisation or delivery systems. The ImmuTune technologies will be developed with partners interested in the up-regulation of T cells as an adjunct to cancer therapies or the down-regulation of T cells in autoimmune diseases, allergic asthma or transplantation.
|
|
|
|
